Abstract
Since the association of circulating DNA level changes with tumor growth was discovered many attempts have been made to develop the sensitive and robust blood-based tests for early tumor diagnostics. Both genomic as well as mitochondrial DNA quantification in the circulation have been extensively evaluated as a diagnostic and prognostic tool to monitor cancer therapy. Cell-free DNA bearing the same genetic and epigenetic changes as the tumor tissues were shown to be detectable in plasma / serum of cancer patients indicating the principal possibility to create the minimally invasive diagnostic tests based on tumor-specific DNA markers. Apart from circulating DNA, tumor-derived RNA in plasma / serum was found to be a promising approach for the development of cancer markers. Results of the last two years establish the quantification of the tumor-derived microRNAs in plasma / serum as an extremely promising approach for cancer diagnostics. The aim of this publication was to review the recently reported studies on the circulating DNA and RNA in cancer patients and to estimate their impact on making the ongoing research closer to clinical application.
Keywords: Circulating DNA, RNA, cancer, diagnostics, genetic mutations, allelic imbalance, gene methylation, microRNA
Current Molecular Medicine
Title: Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers
Volume: 10 Issue: 2
Author(s): V. V. Vlassov, P. P. Laktionov and E. Y. Rykova
Affiliation:
Keywords: Circulating DNA, RNA, cancer, diagnostics, genetic mutations, allelic imbalance, gene methylation, microRNA
Abstract: Since the association of circulating DNA level changes with tumor growth was discovered many attempts have been made to develop the sensitive and robust blood-based tests for early tumor diagnostics. Both genomic as well as mitochondrial DNA quantification in the circulation have been extensively evaluated as a diagnostic and prognostic tool to monitor cancer therapy. Cell-free DNA bearing the same genetic and epigenetic changes as the tumor tissues were shown to be detectable in plasma / serum of cancer patients indicating the principal possibility to create the minimally invasive diagnostic tests based on tumor-specific DNA markers. Apart from circulating DNA, tumor-derived RNA in plasma / serum was found to be a promising approach for the development of cancer markers. Results of the last two years establish the quantification of the tumor-derived microRNAs in plasma / serum as an extremely promising approach for cancer diagnostics. The aim of this publication was to review the recently reported studies on the circulating DNA and RNA in cancer patients and to estimate their impact on making the ongoing research closer to clinical application.
Export Options
About this article
Cite this article as:
Vlassov V. V., Laktionov P. P. and Rykova Y. E., Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers, Current Molecular Medicine 2010; 10 (2) . https://dx.doi.org/10.2174/156652410790963295
DOI https://dx.doi.org/10.2174/156652410790963295 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Uracil Analogs with Exocyclic Methylidene Group as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry An In Silico Immunogenicity Analysis for PbHRH: An Antiangiogenic Peptibody by Fusing HRH Peptide and Human IgG1 Fc Fragment
Current Bioinformatics Immune Checkpoint Inhibition: Therapeutic Implications in Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer–A Single Institution Experience
Current Radiopharmaceuticals Preface: MicroRNA as Disease Biomarkers
MicroRNA Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
Current Medicinal Chemistry Specialisation of the Tropomyosin Composition of Actin Filaments Provides New Potential Targets for Chemotherapy
Current Cancer Drug Targets Effects of CAP-regimen Chemotherapy on Blood Redox Status in Patients with Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry Engineering Antibodies for Therapy
Current Pharmaceutical Biotechnology The Human Indoleamine 2,3-Dioxygenase Gene and Related Human Genes
Current Drug Metabolism Editorial (Thematic Issue: Optimizing Treatment in Rheumatoid Arthritis)
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of 2, 4, 5-Triphenylimidazole Derivatives with Preliminary SAR
Letters in Drug Design & Discovery 3D-QSAR and Molecular Docking Studies on Design Anti-Prostate Cancer Curcumin Analogues
Current Computer-Aided Drug Design Epigenetics in Vascular Disease – Therapeutic Potential of New Agents
Current Vascular Pharmacology Targeting Transcription Factors in Acute Leukemia in Children
Current Drug Targets The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Src Family Nonreceptor Tyrosine Kinases as Molecular Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Therapy: Latest Developments, Trends and Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design